Smoking is the single largest cause of bladder cancer, responsible for roughly half of all cases in both men and women. Beyond tobacco, a mix of occupational exposures, environmental contaminants, chronic inflammation, certain medications, and genetic factors all play a role. Most bladder cancers develop in the urothelium, the inner lining of the bladder, where cells are in constant contact with whatever the body filters through urine.
Smoking and Tobacco Use
About 50% of bladder cancer cases in men and a similar proportion in women can be attributed to smoking. Current smokers face roughly three times the risk of someone who has never smoked. The connection is straightforward: your kidneys filter carcinogens from tobacco smoke out of the blood and concentrate them in urine, where they sit against the bladder lining for hours at a time.
One of the key chemicals involved is beta-naphthylamine, a known bladder carcinogen. Ironically, changes in cigarette manufacturing over the past 50 years that reduced tar and nicotine appear to have increased the concentration of beta-naphthylamine and other cancer-causing nitrosamines. So while cigarettes may feel “lighter,” they haven’t become safer for the bladder. Quitting does reduce risk over time, though former smokers still carry higher risk than people who never smoked.
Workplace Chemical Exposures
Certain industrial chemicals, particularly a class called aromatic amines, are well-established bladder carcinogens. Two of the most significant are 2-naphthylamine and benzidine. Workers who handle or synthesize these compounds face elevated risk, and the cancers can appear decades after exposure ended.
The industries with the highest historical exposure include chemical manufacturing, dyestuff production, and rubber manufacturing. Modern workplace regulations have reduced exposure levels considerably in many countries, but bladder cancer’s long latency period (often 20 to 30 years) means cases linked to past exposures still appear today. If you worked in these industries, that history is worth mentioning to a doctor during any urinary workup.
Arsenic in Drinking Water
Arsenic contamination in well water or municipal supplies is a significant but often overlooked risk factor. A systematic review spanning 30 years of evidence found that drinking water with arsenic at just 10 micrograms per liter, the current maximum allowed in U.S. public water systems, may roughly double the risk of bladder cancer. At 50 micrograms per liter, risk increases roughly fourfold. At 150 micrograms per liter, it climbs nearly sixfold.
This is especially relevant in regions with naturally high groundwater arsenic, including parts of South and Southeast Asia, South America, and some areas of the western United States. Private wells are not subject to the same monitoring requirements as municipal systems, so if you rely on well water, testing for arsenic is a practical step.
Chronic Inflammation and Infection
Long-term irritation of the bladder lining can trigger a different type of bladder cancer called squamous cell carcinoma, rather than the more common urothelial type. The most globally significant cause of this is infection with the parasitic worm Schistosoma haematobium, which is endemic in parts of Africa and the Middle East. In Egypt, for example, squamous cell carcinoma of the bladder was found in 10 out of every 1,000 adults infected with the parasite, compared to 0 to 3 per 1,000 in uninfected individuals. Higher worm burdens correlate with higher cancer risk.
The mechanism involves a two-hit process. First, inflammation at the infection site generates reactive oxygen molecules and other compounds that directly damage DNA. Second, the physical damage to the bladder lining triggers constant cell turnover to repair the tissue, and that rapid division gives damaged cells more opportunities to become cancerous. Bacteria commonly present in infected urine can also convert dietary compounds into cancer-promoting nitrosamines, adding another layer of risk.
Outside of schistosomiasis, repeated urinary tract infections, chronic catheter use, and conditions causing long-term bladder inflammation (such as paraplegia requiring catheterization) have also been linked to increased bladder cancer risk through similar mechanisms.
Prior Pelvic Radiation Therapy
People who received radiation treatment for prostate, cervical, or uterine cancer face an elevated risk of developing bladder cancer as a secondary cancer. In a large study of prostate cancer patients, 1.16% of those who received external beam radiation went on to develop bladder cancer, compared to 0.81% of those treated without radiation.
The risk grows with time. In the first 10 years after radiation, the relative risk roughly doubles compared to non-radiated patients. After 20 years, it nearly triples. Women treated with radiation for cervical or uterine cancer face particularly elevated risk, with roughly 2.5 to 3 times the likelihood of bladder cancer compared to those treated without radiation. This long latency is why continued monitoring matters years or even decades after cancer treatment ends.
Certain Medications
A small number of medications have been linked to bladder cancer. Pioglitazone, a drug used to manage type 2 diabetes, was associated with a 63% increased risk of bladder cancer in a large population study with up to 14.5 years of follow-up. Notably, rosiglitazone, a closely related diabetes drug in the same class, showed no such increase, suggesting the risk is specific to pioglitazone’s unique pharmacological activity rather than a shared class effect.
Cyclophosphamide, a chemotherapy drug used for various cancers and some autoimmune conditions, is another recognized risk factor. It produces a metabolite that concentrates in urine and irritates the bladder lining, sometimes causing a condition called hemorrhagic cystitis that can progress to cancer over time.
Why Men Get Bladder Cancer More Often
Men are diagnosed with bladder cancer at roughly three to four times the rate of women. In the U.S., the overall incidence rate is about 18 per 100,000 people per year, but the split is heavily skewed toward men. Historically, this was attributed mainly to higher rates of smoking and occupational exposure. That explanation is incomplete.
Biological differences play a real role. Male smokers have a higher risk of bladder cancer than female smokers, even when accounting for how much they smoke, pointing to metabolic differences in how men and women process tobacco carcinogens. Chromosomal factors also matter in surprising ways. Loss of the Y chromosome in aging men appears to increase cancer risk. Meanwhile, having an extra copy of the X chromosome seems to protect against bladder cancer: men with Klinefelter syndrome (who carry an extra X) have significantly reduced rates of solid tumors, while women with Turner syndrome (who are missing part or all of one X chromosome) have elevated bladder cancer risk. These effects appear to be independent of sex hormones.
Genetic Mutations in Tumor Cells
Two genetic mutations show up repeatedly in bladder tumors. One, found in a gene called FGFR3, is most common in low-grade, early-stage tumors that tend to recur but rarely become life-threatening. The other, in the tumor suppressor gene TP53, is most common in high-grade, aggressive tumors that are more likely to invade the muscle wall of the bladder and spread. These are not inherited mutations in most cases. They develop in bladder cells over a person’s lifetime, driven by the carcinogenic exposures described above.
Understanding which mutations a tumor carries has become increasingly important for treatment decisions. Tumors with FGFR3 mutations, for instance, may respond to targeted therapies designed to block that specific growth signal.
How These Risk Factors Shape Survival
Bladder cancer caught early is highly treatable. Half of all cases are diagnosed while still confined to the innermost cell layer, and these carry a five-year survival rate of nearly 98%. Another 34% are caught while still localized to the bladder, with a five-year survival of about 73%. Once the cancer spreads to nearby lymph nodes, survival drops to around 41%, and for distant metastatic disease it falls to roughly 9%. The overall five-year survival rate across all stages is 79%.
Because so many of the causes involve prolonged, low-level exposure, the typical bladder cancer patient is diagnosed later in life. The most actionable takeaway from the research is that the biggest single risk factor, smoking, is also the most modifiable. Occupational awareness, clean drinking water, and attention to urinary symptoms (particularly blood in the urine, even once) round out the practical steps that make a real difference.